

PE anti-human HLA-DR, DP, DQ

Catalog # / Size: 2408580 / 100 tests
2408575 / 25 tests

Clone: Tü39

Isotype: Mouse IgG2a, κ


Immunogen: Human PBL

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD19 Alexa Fluor® 488 and HLA-DR, DP, DQ (clone Tü39) PE (left) or Mouse IgG2a, κ PE isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: Tü39 has been reported to react with a shared epitope of HLA-DR, HLA-DP, and HLA-DQ.

Additional reported applications (of relevant formats) include immunoprecipitation⁶, *in vitro* blocking of MLR⁵, and suppressor cell generation⁴.

- Application References:**
1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
 2. Qvigstad E, *et al.* 1984. *Hum. Immunol.* 11:207.
 3. Serenius B, *et al.* 1984. *EMBO J.* 3:3209.
 4. Ottenhoff TH, *et al.* 1985. *Hu*

Description: HLA-DR, HLA-DP, and HLA-DQ are heterodimeric cell surface glycoproteins comprised of an α (heavy) chain and a β (light) chain. They are expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells, and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Variations in the HLA gene expression are crucial to graft survival.

- Antigen**
- References:**
1. Thorsby E. 1974. *Transplant. Rev.* 18:51.
 2. Qvigstad E, et al. 1984. *Hum. Immunol.* 11:207.
 3. Servenius B, et al. 1984. *EMBO J.* 3:3209.
 4. Ottenhoff TH, et al. 1985. *Hum. Immunol.* 13:105.
 5. Strassmann G, et al. 1985. *Hum. Immunol.* 13:125.
 6. Trowsdale J, et al. 1985. *Immunol Rev.* 85:5.